Google
SMTI 株価分析 — SANARA MEDTECH INC (Healthcare >> Medical Instruments & Supplies)
SMTI に関するよくある質問
SMTIのPER（株価収益率）は？
SANARA MEDTECH INC（SMTI）は現在PER 242.08倍で取引されています。
SMTIのROE（自己資本利益率）は？
SANARA MEDTECH INCのROEは-477.72%です。
SMTIの配当利回りは？
SANARA MEDTECH INCの配当利回りは0.00%です。
SMTIの品質スコア（Quality Score）は？
当社のAIはSMTIの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
SMTIは今が買い時ですか？
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
SMTIはどのセクターに属しますか？
SANARA MEDTECH INCはHealthcare >> Medical Instruments & Suppliesセクターに分類されます（NASDAQ市場）
SMTI AI Analysis Summary
Our AI summary for SMTI: SANARA MEDTECH INC (NASDAQ), Healthcare >> Medical Instruments & Supplies sector. The stock currently trades at a P/E of 242.08, ROE of -477.72%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 33.86
Price
-0.20
(-0.59%)
Day Change
|
|
|---|
SMTI, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 33.86 |
| PBV / Sector |
44.61 / 3.37
|
| Earning Per Share | -3.63 |
| PE / Sector |
242.08 / 44.25
|
| PEG or PE/Growth / Sector |
2.06 / -1.35
|
| Average 1M Daily Value |
8.36 M
|
| Average 1W Daily Value |
28.22 M
GREAT
|
| Timing Factors |
|
85% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:30 |
| Symbol | SMTI |
| Name | SANARA MEDTECH INC |
| Sector | Healthcare >> Medical Instruments & Supplies |
| Market | NASDAQ |
| Listed Shares | 9.19 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 313.12 / 16,159.14 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1200 Summit Avenue, Fort Worth, TX, United States, 76102
Phone: 817 529 2300
Website: https://sanaramedtech.com
Employees: 108
Description: Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Instruments & Supplies
Click a bubble to view stock details · Bubble size represents market capitalization share
